Immunovia
Diagnostics company developing a blood test for early pancreatic cancer detection.
IMMNOV | ST
Overview
Corporate Details
- ISIN(s):
- SE0006091997 (+2 more)
- LEI:
- 549300KHWL6KK1XGUO81
- Country:
- Sweden
- Address:
- Scheelevägen 8, 223 63 LUND
- Website:
- https://immunovia.com/
- Industry:
- Other human health activities
Description
Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2018-11-07 08:30 | English | PDF • 482.3 KB | |||
| 2018-10-26 11:26 |
Valberedning utsedd inför årsstämma 2019 i Immunovia AB (Publ)
|
Swedish | PDF • 437.9 KB | ||
| 2018-10-26 11:26 |
Immunovia AB (Publ) nomination committee appointed for AGM 2019
|
English | PDF • 437.1 KB | ||
| 2018-10-08 13:41 |
Immunovia announces strategic focus centered on IMMray™ blood-based biomarker s…
|
English | PDF • 684.2 KB | ||
| 2018-10-08 13:41 |
Immunovia annonserar strategiskt fokus på IMMray® blodbaserade biomarkörssignat…
|
Swedish | PDF • 303.1 KB | ||
| 2018-09-28 08:30 |
Increase in share capital and number of shares in Immunovia
|
English | PDF • 559.8 KB | ||
| 2018-09-28 08:30 |
Nytt aktiekapital och antal aktier i Immunovia
|
Swedish | PDF • 561.8 KB | ||
| 2018-08-24 08:30 |
Immunovia Interim report, January-June 2018
|
English | PDF • 405.4 KB | ||
| 2018-08-24 08:30 |
Immunovia delårsrapport, januari-juni 2018
|
Swedish | PDF • 397.8 KB | ||
| 2018-08-24 08:00 | Swedish | PDF • 397.8 KB | |||
| 2018-08-24 08:00 | English | PDF • 405.4 KB | |||
| 2018-08-22 14:23 |
Breakthrough in autoimmune testing – IMMrayTM based novel biomarker signature i…
|
English | PDF • 536.3 KB | ||
| 2018-08-22 14:23 |
Genombrott inom autoimmun testning - en IMMray ™-baserad biomarkörssignatur ide…
|
Swedish | PDF • 435.4 KB | ||
| 2018-08-16 17:35 |
Resultat från retrospektiv studie för IMMray® PanCan-d visar att Immunovia behö…
|
Swedish | PDF • 572.2 KB | ||
| 2018-08-16 17:35 |
Retrospective study results for IMMray™ PanCan-d conclude Immunovia needs to do…
|
English | PDF • 584.3 KB |
Automate Your Workflow. Get a real-time feed of all Immunovia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunovia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunovia via our API.
Peer Companies
